NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 2 FDA
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03675737 2026-02-27KEYNOTE-859Merck Sharp & Dohme LLCPhase 3 Completed1,579 enrolled 31 charts 2 FDA
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 2 FDA
NCT03615326 2025-12-11MK-3475-811Merck Sharp & Dohme LLCPhase 3 Completed738 enrolled 22 charts 6 FDA
NCT02872116 2025-08-07CheckMate649Bristol-Myers SquibbPhase 3 Completed2,031 enrolled 19 charts 2 FDA
NCT02052778 2025-03-27A Study of TAS-120 in Patients With Advanced Solid TumorsTaiho Oncology, Inc.Phase 1/2 Completed407 enrolled 45 charts 2 FDA
NCT02500043 2024-09-03Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric CancerTaiho Oncology, Inc.Phase 3 Completed507 enrolled 17 charts 1 FDA
NCT02335411 2022-08-08KEYNOTE-059Merck Sharp & Dohme LLCPhase 2 Completed318 enrolled 24 charts 1 FDA